Skip to content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Comprehensive geriatric assessment in patients undergoing transcatheter aortic valve implantation – results from the CGA-TAVI multicentre registry

  • Andrea Ungar1Email author,
  • Giulio Mannarino1,
  • Nathalie van der Velde2,
  • Jan Baan3,
  • Marie-Pierre Thibodeau4,
  • Jean-Bernard Masson4,
  • Gennaro Santoro1,
  • Martijn van Mourik3,
  • Sofie Jansen2,
  • Cornelia Deutsch5,
  • Peter Bramlage5View ORCID ID profile,
  • Jana Kurucova6,
  • Martin Thoenes6,
  • Stefania Maggi7 and
  • Andreas W. Schoenenberger8
BMC Cardiovascular DisordersBMC series – open, inclusive and trusted201818:1

https://doi.org/10.1186/s12872-017-0740-x

Received: 1 September 2017

Accepted: 14 December 2017

Published: 4 January 2018

Abstract

Background

In older patients with aortic stenosis (AS) undergoing TAVI, the potential role of prior CGA is not well established. To explore the value of comprehensive geriatric assessment (CGA) for predicting mortality and/or hospitalisation within the first 3 months after transcatheter aortic valve implantation (TAVI).

Methods

An international, multi-centre, prospective registry (CGA-TAVI) was established to gather data on CGA results and medium-term outcomes in geriatric patients undergoing TAVI. Logistic regression was used to evaluate the predictive value of a multidimensional prognostic index (MPI); a short physical performance battery (SPPB); and the Silver Code, which was based on administrative data, for predicting death and/or hospitalisation in the first 3 months after TAVI (primary endpoint).

Results

A total of 71 TAVI patients (mean age 85.4 years; mean log EuroSCORE I 22.5%) were enrolled. Device success according to VARC criteria was 100%. After adjustment for selected baseline characteristics, a higher (poorer) MPI score (OR: 3.34; 95% CI: 1.39–8.02; p = 0.0068) and a lower (poorer) SPPB score (OR: 1.15; 95% CI: 1.01–1.54; p = 0.0380) were found to be associated with an increased likelihood of the primary endpoint. The Silver Code did not show any predictive ability in this population.

Conclusions

Several aspects of the CGA have shown promise for being of use to physicians when predicting TAVI outcomes. While the MPI may be useful in clinical practice, the SPPB may be of particular value, being simple and quick to perform. Validation of these findings in a larger sample is warranted.

Trial registration

The trial was registered in ClinicalTrials.gov on November 7, 2013 (NCT01991444).

Keywords

Transcatheter aortic valve implantation (TAVI)Comprehensive geriatric assessment (CGA)Multidimensional prognostic index (MPI)Short physical performance battery (SPPB)Silver code

Background

Severe symptomatic stenosis of the aortic valve (aortic stenosis; AS) is associated with mortality of up to 50% at 1 year if left untreated [1, 2]. The outcome of surgical aortic valve replacement (SAVR) is generally predicted with the aid of quantitative scales such as the EuroSCORE or the Society of Thoracic Surgeons (STS) risk score. However, the accuracy of such algorithms for assessing older-age, multi-morbid patients undergoing transcatheter aortic valve implantation (TAVI) is low [35]. This is mainly due to the absence of variables related to ageing, such as frailty, mental status, social support, and overall health. There is evidence that additionally evaluating these factors can help provide a more precise estimation of an older person’s response to treatment [3, 6, 7]. Indeed, a recent report from the American College of Cardiology (ACC) advocates assessment of frailty and cognitive function prior to determining a patient’s suitability for TAVI [8]. The inclusion of a geriatrician in the Heart Team responsible for assessing patients prior to TAVI may therefore be warranted [9].

A comprehensive geriatric assessment (CGA) is a multidimensional diagnostic process for evaluating an individual’s clinical, psychosocial, and functional characteristics [10, 11]. It usually consists of functional tests complementing usual clinical evaluation. For example, CGA may include the calculation of a multidimensional prognostic index (MPI) based on mental and nutritional status, number of co-morbid conditions and medications, living arrangements, and the ability to cope with activities of daily living [12, 13]. Pilotto et al. showed that the MPI had high predictive power for assessing mortality after hospitalisation of older patients [13]. For TAVI specifically, few studies have evaluated CGA and its components for outcome prediction [3, 1416]. For example, Stortecky et al. evaluated a geriatric assessment that contained many of the same components as the MPI, and found that many of the included items were predictive of mortality and the occurrence of a major adverse cardiac or cerebrovascular event (MACCE) at 30 days and 1 year after the procedure [14]. All previous studies originated from single-centre experiences.

We aimed to determine the power of CGA for predicting the combined endpoint of mortality and stroke within the 3 months subsequent to TAVI based on data from a multi-centre, prospective cohort. We further characterised changes in CGA over time, and provide additional evidence for the utility of TAVI in a geriatric, comorbid population.

Methods

Patients and registry design

The CGA-TAVI registry is a prospective, international, multi-centre, observational registry [17]. Patients were enrolled at three centres in Italy (Careggi Hospital, Florence), the Netherlands (Academic Medical Center, Amsterdam) and Canada (Centre Hospitalier de l’Université de Montréal) between August 2013 and December 2015. Individuals were eligible if they were aged >80 years, had symptomatic severe calcific aortic valve (AV) stenosis, and were assigned to undergo transaortic, transapical or transfemoral TAVI. Patients were excluded if TAVI was being performed as an emergency procedure or if patients were unable to participate in the follow-up. Overall, 603 patients underwent TAVI at one of the three study centres during the study period (Italy: 68, Canada: 95; the Netherlands: 440. Of these, 71 patients were enrolled in the CGA-TAVI registry: 41, 15 and 15 from the sites in Italy, Canada and the Netherlands, respectively.

Baseline assessment

A detailed description of the information documented has been previously published [17]. Briefly, data regarding demographics, comorbidities, and prior cardiovascular interventions were collected at hospital admission. A CGA was performed by a geriatrician for each patient. This included calculation of the MPI [12, 13], which consisted of the following components: Activities of Daily Living (ADL; 6 items) [18, 19]; Instrumental Activities of Daily Living (IADL; 8 items) [20]; Short Portable Mental Status Questionnaire (SPMSQ; 10 items) [21]; Cumulative Illness Rating Scale (CIRS; 14 items) [22, 23]; Mini Nutritional Assessment (MNA; 18 items) [24]; Exton-Smith Scale (ESS; 5 items) [25]; number of drugs used (1 item); and co-habitation status (1 item). In each case, a tripartite hierarchy was used for scoring (no problems: 0 points; minor problems: 0.5 points; severe problems: 1 point). The boundaries for these scores were based on the cut-off points derived from the associated literature [12]. A Silver Code value was also calculated from administrative data for further prognostic stratification [26] and a Short Physical Performance Battery (SPPB) was performed, which involved repeated chair stands, balance testing, and an 8-ft (2.44 m) walk [27]. Detailed breakdowns of the three assessment scores can be found in Appendices 1, 2 (MPI), 3 (Silver Code) and 4 (SPPB). Procedural characteristics were also documented.

Follow-up assessment and outcomes

Patients were scheduled for follow-up at discharge, 30 days and 3 months post-procedure. These visits were conducted at the patient’s enrolling centre and involved repetition of the CGA performed at the baseline assessment. Death, all-cause hospitalisation, TAVI-related hospitalisation, stroke, transient ischaemic attack (TIA), myocardial infarction (MI), life-threatening bleeding, acute kidney injury, coronary artery obstruction requiring intervention, major vascular complications, valve dysfunction requiring repeat procedure, or worsening congestive heart failure (CHF) were recorded, as defined in the Valve Academic Research Consortium-2 (VARC-2) consensus document [28].

Endpoints

The primary endpoint was death and/or hospitalisation within the first 3 months after TAVI. The secondary endpoint was death and/or non-fatal stroke within the same period. Changes in the scores of the components of the CGA from baseline to 3 months were also evaluated.

Data management and statistics

Data were entered into an online database via the completion of an electronic case report form (eCRF; s4trials, Berlin, Germany). Details were automatically checked for plausibility and completeness.

Data were analysed using descriptive statistics, with categorical variables presented as absolute values and percentages and continuous variables as means with standard deviations (SD). A logistic regression was used to evaluate the predictive value of CGA components (MPI, SPBB and Silver Code) for the primary/secondary endpoints. Age, gender, New York Heart Association (NYHA) class and surgical risk (EuroSCORE/STS) were used as co-variables. Logistic regression results are presented as odds ratios (OR) with 95% Wald confidence limits (95% CI) and p-values. CGA changes from baseline to 3-month follow-up were tested for significance using a t-test. P-values of <0.05 were considered significant.

Data were analysed using IBM SPSS statistics version 24 (IBM corporation, Amonk, New York, USA).

Results

Baseline patient characteristics

Overall, 44 patients (62%) were female. Means for age and body mass index (BMI) were 85.4 ± 2.9 years and 24.7 ± 3.7 kg/m2, respectively (Table 1). The most prevalent comorbidity was hypertension (83.1%), followed by coronary artery disease (53.5%), peripheral artery disease (28.2%), diabetes mellitus (26.8%), prior MI (23.9%), and pulmonary disease (15.5%). In terms of surgical risk, the mean log EuroSCORE and STS scores were 22.5 ± 13.2% and 5.8 ± 3.9%, respectively.
Table 1

Patient characteristics

 

Mean ± SD (n) / n/N (%)

Age [years]

85.4 ± 2.9 (n = 71)

Gender [female]

44/71 (62.0)

BMI [kg/m2]

24.7 ± 3.7 (n = 71)

Comorbidities

 Hypertension

59/71 (83.1)

 Diabetes mellitus

19/71 (26.8)

 PAD

20/71 (28.2)

 Prior stroke/TIA

6/71 (8.5)

 CAD

38/71 (53.5)

 Prior MI

17/71 (23.9)

 Pulmonary diseasea

11/71 (15.5)

 Pulmonary hypertension

35/71 (49.3)

 Creatinine ≥2.0 mg/dlb

5/71 (7.0)

 Dialysis

2/71 (2.8)

Prior cardiovascular intervention

 PCI

16/71 (22.5)

 CABG

13/71 (18.3)

 Mitral valve replacement

2/71 (2.8)

 Tricuspid valve replacement

0/71 (0)

 Balloon aortic valvuloplasty

6/71 (8.5)

 PPI

5/71 (7.0)

Surgical risk

 Log EuroSCORE I

22.5 ± 13.2 (n = 71)

 STS risk score

5.8 ± 3.9 (n = 71)

AS-related symptoms (%)

 Syncope

5/71 (7.0)

 Dizziness with exertion

5/71 (7.0)

 CCS angina grade

  Class III

7/70 (10.0)

  Class IV

0/70 (0)

 NYHA classification

  Class III

50/71 (70.4)

  Class IV

7/71 (9.9)

AS echocardiographic parameters

 AV peak gradient (mmHg)

78.5 ± 17.8 (n = 59)

 AV mean gradient (mmHg)

50.5 ± 14.1 (n = 61)

 Vmax (m/s)

4.2 ± 0.9 (n = 24)

 Effective orifice area (cm2)

0.9 ± 0.6 (n = 37)

 LVEF (%)

50.9 ± 12.0 (n = 62)

Legend: BMI body mass index, PAD peripheral artery disease, TIA transient ischaemic attack, CAD coronary artery disease, MI myocardial infarction, PCI percutaneous coronary intervention, CABG coronary artery bypass grafting, PPI permanent pacemaker implantation, log Euro SCORE logistic European System for Cardiac Operative Risk Evaluation, STS Society of Thoracic Surgeons, AS aortic stenosis, LVEF left ventricular ejection fraction, AV aortic valve, CCS Canadian Cardiovascular Society, NYHA New York Heart Association, V max maximum velocity

aDefined as chronic obstructive pulmonary disease, asthma, a forced expiratory volume-1 of < 1.0, or oxygen dependency

bExcluding patients with dialysis

The majority of patients were at NYHA class III (70.4%) or IV (9.9%). Further AS-related symptoms were class III angina (10.0%), dizziness with exertion (7.0%), and syncope (7.0%). Regarding echocardiography, peak and mean AV gradients were 78.5 ± 17.8 and 50.5 ± 14.1 mmHg, respectively, with a left ventricular ejection fraction (LVEF) of 50.9 ± 12.0%, a mean Vmax of 4.2 ± 0.9 m/s, and an effective orifice area of 0.9 ± 0.6 cm2.

Procedural characteristics and periprocedural outcomes

Details about procedural aspects are provided in the supplementary data (Appendix 5). Devices were placed successfully (as defined by VARC-2 [28]) in all patients (Appendix 6). The rate of intraoperative complications was 17.1%, which were vascular complications requiring treatment in 10.0% of patients and access-related in 5.6%. No conversion to open surgery was necessary. Paravalvular regurgitation was moderate in 2.9%, with no severe regurgitation. Post-procedural AV peak and mean gradients were 20.0 ± 12.4 and 11.3 ± 7.2 mmHg, respectively.

Outcomes at 3-months

In total, 6 patients died (8.5%) and 9 were hospitalised (13.8%) by the 3-month follow-up. The primary endpoint (death and/or hospitalisation in the first 3 months) was observed in 13/71 patients (18.3%) (Table 2). After adjustment for baseline characteristics, a higher (poorer) MPI score (OR: 3.34; 95% CI: 1.39–8.02; p = 0.0068) and a lower (poorer) SPPB score (OR: 1.15; 95% CI: 1.01–1.54; p = 0.0380) were found to be associated with an increased odds of primary endpoint achievement (Table 3).
Table 2

Short- and medium-term outcomes

 

≤30 daysa

n/N (%)

≤3 months

n/N (%)

Primary endpoint

(Death and/or hospitalisation)

5/70 (7.1)

13/71 (18.3)

Secondary endpoint

(Death and/or non-fatal stroke)

2/71 (2.8)

6/71 (8.5)

All-cause mortality

2/71 (2.8)

6/71 (8.5)

Non-fatal complications

(n = 69)

(n = 65)

 All-cause hospitalisation

5/69 (7.2)

9/65 (13.8)

 Valve-related hospitalisation

3/69 (4.3)

2/65 (6.2)

 Non-fatal stroke

0/69 (0.0)

0/62 (0.0)

 Acute kidney injury (stage 2 or 3)

3/69 (4.3)

5/64 (7.8)

 Major vascular complication

1/69 (1.4)

0/64 (3.1)

 Repeat procedure for valve dysfunction

0/69 (0)

1/62 (1.6)

 Myocardial infarction

0/69 (0)

0/62 (0)

 PPI

9/69 (13.0)

9/65 (13.8)

Legend: CHF congestive heart failure, MI myocardial infarction, NYHA New York Heart Association, CCS Canadian Cardiovascular Society, PPI permanent pacemaker implantation

a≤ 30 days includes all complications which occurred periprocedurally, during the phase of hospitalisation for TAVI and after discharge within 30 days

Table 3

Logistic regression for the prediction of events at 3 months by CGA at baseline

 

Univariable OR (95% CI)

p-value

Multivariable OR (95% CI)

p-value

Death and/or hospitalisation

 Increasing MPI score (high vs. low)

0.66 (0.54–0.81)

< 0.0001

3.34 (1.39–8.02)a

0.0068

 Decreasing SPPB (low vs. high)

1.35 (1.19–1.53)

< 0.0001

1.15 (1.01–1.54)

0.0380

 Increasing Silver Code (high vs. low)

0.94 (0.92–0.97)

< 0.0001

1.03 (0.91–1.15)

0.6576

Death and/or non-fatal stroke

 Increasing MPI score (high vs. low)

0.49 (0.36–0.63)

< 0.0001

4.75 (1.40–16.08)

0.0123

 Decreasing SPPB (low vs. high)

1.89 (1.36–2.64)

0.0002

1.62 (1.08–2.43)

0.0188

 Increasing Silver Code (high vs. low)

0.90 (0.87–0.94)

< 0.0001

1.04 (0.87–1.23)

0.6938

Legend: MPI multidimensional prognostic index, SPPB short physical performance battery. All values adjusted for age, gender, NYHA class and surgical risk (EuroSCORE)

aThe direction of the OR changed with the introduction of age into the model

The secondary endpoint (death and/or non-fatal stroke in the first 3 months) was observed in 6 patients (8.5%) (Table 2). After multivariate adjustment, a higher (poorer) MPI score (OR: 4.75; 95% CI: 1.40–16.08; p = 0.0123) and a lower (poorer) SPPB score (OR: 1.62; 95% CI: 1.08–2.43; p = 0.0188) were associated with a greater odds of secondary endpoint achievement (Table 3).

CGA change from baseline to 3 months

Between baseline and 3 months, the total MPI score decreased only slightly, from a mean of 0.34 ± 0.11 to 0.30 ± 0.13 (mean intra-individual change: −0.02 ± 0.12; p = 0.25) (Appendix 7). However, the CIRS and ESS components changed by a statistically significant amount (−0.12 ± 0.25; p < 0.001 and −0.04 ± 0.13; p = 0.04, respectively). While the change in Silver Code was small, the SPPB score increased significantly (+1.86 ± 2.76; p < 0.001).

Discussion

Of the multiple components of the CGA that were evaluated, the MPI and the SPPB both had value for predicting the likelihood of death and/or hospitalisation in the first 3 months following TAVI. In terms of time-efficiency, the SPPB appears to be the favourable approach, with the MPI perhaps not adding sufficient additional predictive value to warrant such a time-consuming assessment.

Outcomes

In our patients, the rate of all-cause mortality at 30 days (2.8%) was within the range (1.1%–5.9%) reported by large-scale studies in patients with a similar level of surgical risk and mean ages above 80 years, such as the PARTNER II trial and SOURCE 3, WIN-TAVI, Swiss TAVI, and PRAGMATIC registries [2933]. Though a less commonly reported outcome, the same was true of the rate of rehospitalisation (7.2% vs. 4.6% in the PARTNER II SAPIEN 3 trial and 6.5% in the overall PARTNER II trial) [29, 34]. Variations in rates between studies are likely due to differing patient characteristics, access routes, and the valves/delivery devices available during study periods. Our findings regarding three-month outcomes could not be easily compared to previous studies, as this time-point is not largely reported upon in the literature.

Surgical risk scores

EuroSCORE and STS algorithms are conventional tools for assessing cardiac operative risk. It has been suggested that the latter is slightly more accurate in TAVI patients [4, 5], though neither are ideal. Patients in the present study had expected mortality rates of 22.5% (EuroSCORE I) and 5.8% (STS), and though the latter was closer to the observed rate, both were excessively elevated. Even the more up-to-date EuroSCORE II has been shown to have suboptimal discriminatory power, suggesting the need for alternative or additional assessment tools [35, 36].

Multidimensional prognostic index

Use of a CGA during clinical assessment of operative risk in AS patients has been suggested as a way to address the shortcomings of the EuroSCORE and STS score, and better predict outcomes [17, 36]. In the present study, both MPI and SPPB were found to have predictive value for determining the likelihood of short-term mortality/hospitalisation or stroke after TAVI. Interestingly, while high MPI was a “negative predictor” in the univariate analysis, it became a “positive predictor” after adjusting for age, gender, NYHA class and surgical risk. This change of direction can be explained by the clinical setting; younger patients with a low MPI are typically treated with SAVR, while elderly patients with a high MPI are unlikely to be treated at all. Consequently, our TAVI population was likely composed of patients with a lower age and high MPI or a higher age and low MPI, resulting in a switch of the direction of the odds ratio at multivariate analysis. This reflection of the clinical context is supportive of the “real” association between MPI score and outcomes.

Though no other studies appear to have specifically reported on the predictive value of MPI in TAVI, several have shown higher MPI scores to be significantly associated with greater rates of mortality in older patients with a variety of acute illnesses, including heart failure and TIA [12, 13, 3740]. Other studies have evaluated other multi-component models for predicting mortality and morbidity after cardiac surgery [41]. For TAVI specifically, Green et al. found that patients with a high frailty score, as determined by gait speed, grip strength, serum albumin and ADL, were at greater risk of one-year mortality [15]. The five-component frailty score proposed by Kamga et al. was found to predict one-year mortality after transfemoral TAVI [16]. Stortecky et al. identified numerous parameters in their Multidimensional Geriatric Assessment that were predictive of 30-day and one-year mortality and MACCE after TAVI [14]. Data from the PARTNER trial were used to construct models for predicting a poor outcome, defined as death or a low/significantly decreased quality of life, after TAVI [42]. These models were subsequently validated in a large multi-centre cohort of TAVI patients, with an incremental increase in discriminative ability identified on the addition of markers of frailty and disability [43]. In agreement with the data from our CGA registry, these studies demonstrate the potential value of such multi-component analyses for predicting outcome after TAVI.

Short physical performance battery

A significant drawback of these multidimensional evaluation tools, however, is that they are extremely time-consuming. In the present work, we found that use of the SPPB alone was equally as effective as the MPI for predicting death and/or hospitalisation, and death and/or non-fatal stroke, in the first 3 months after TAVI. This short series of tests is recommended by the European Union Geriatric Medicine Society (EUGMS) as part of a CGA in older AS patients [17], although it appears that there is little published evidence in support of using it for assessing TAVI candidates specifically. The concept of tests of physical ability to predict outcome after cardiac surgery has been evaluated in other studies. Afilalo et al. demonstrated that a slow 5-m gait speed was associated with a greater risk of operative mortality and in-hospital mortality and major morbidity in older patients undergoing cardiac surgery [7, 44]. They further determined that use of this parameter alone was superior to a variety of other frailty scales [6]. In patients undergoing TAVI specifically, 5-m gait speed has been shown to be independently associated with 30-day mortality after adjustment for STS score and other relevant baseline characteristics [45]. Stortecky et al. reported that the “timed get-up and go” (TUG) test had the greatest predictive ability of all of the individual geriatric assessment tools that they investigated [14]. In combination with either the STS or EuroSCORE, the TUG was superior to the other components evaluated for predicting all-cause mortality and MACCE during the first year after TAVI. A recent report by the ACC recommends that a 5-m gait speed test and a 6 min walk test be used to assess frailty and physical functioning, respectively, when determining a patient’s suitability for TAVI [8].

The simplicity of physical tests such as the SPPB is not their only advantage, with the lack of subjectivity on the part of both physician and patient providing a level of accuracy that cannot be obtained using questionnaire-based assessment. This is particularly relevant for the advanced-age TAVI population, where cognitive impairment is a potentially significant confounding factor when evaluating self-reported parameters [6].

Silver code

According to our data, the Silver Code had no value for predicting death/hospitalisation or death/stroke during the first 3 months after TAVI. The calculation of this parameter prior to deciding on the suitability of a patient for TAVI is another recommendation of the EUGMS [17]. Previous studies have demonstrated a relationship between Silver Code and one-year mortality, although this was in the setting of the Emergency Department [26, 46]. As the Silver Code is determined from administrative data, it is particularly suited to planned procedures such as TAVI. Therefore, although it was not found to be an independent predictor of outcome in the present analysis, it should perhaps not be discounted. Further evaluation in a larger population may clarify its utility as part of a CGA prior to TAVI.

Limitations

Firstly, as an observational study, inherent limitations such as a higher potential for missing data are present. However, the observational aspect carried several advantages, such as an evaluation of TAVI patients in a real-world setting, avoiding the confounding issue of the strict inclusion and exclusion criteria used for clinical trials. This is particularly important, as geriatric patients are often those excluded due to high levels of comorbidity. Secondly, our findings are currently only applicable to geriatric patients at higher surgical risk. Considering that there is a current shift in clinical practice towards TAVI in lower-risk patients who are normally eligible for surgical heart valve replacement, re-evaluation of CGA in different populations may become necessary. In addition, we were only able to obtain data for a modest number of patients from three participating sites, limiting statistical power and generalisability. Indeed, the relatively low incidence of mortality and stroke at 3 months in a fairly small sample may have resulted in suboptimal power to detect baseline characteristics that are predictive for this outcome. Future studies in larger samples would be useful for clarification.

Conclusion

Several aspects of the CGA have shown promise for being of use to physicians when predicting the likelihood of death, rehospitalisation and non-fatal stroke following TAVI. The strong association between MPI and such outcomes indicates its potential utility in clinical practice. In addition, the SPPB may have significant value, being simple and quick to perform; however, the modest sample size included herein limit the formation of firm conclusions, and validation of these findings in a larger sample of TAVI patients with a greater range of surgical risk is warranted.

Clinical perspectives

The accuracy of conventional surgical risk scores is known to be suboptimal for predicting the outcomes of TAVI in elderly aortic stenosis patients. This study shows a potential benefit of adding items from a comprehensive geriatric assessment (CGA) to pre-intervention assessments. This now requires further validation in larger cohorts.

Abbreviations

ACC: 

American College of Cardiology

AS: 

Aortic stenosis

AV: 

Aortic valve

BMI: 

Body mass index

CGA: 

Comprehensive geriatric assessment

CHF: 

Congestive heart failure

CI: 

Confidence interval

CIRS: 

Cumulative illness rating scale

eCRF: 

Electronic case report form

ESS: 

Exton-Smith Scale

EUGMS: 

European union geriatric medicine society

IADL: 

Instrumental Activities of Daily Living

LVEF: 

Left ventricular ejection fraction

MACCCE: 

Major adverse cardiac or cerebrovascular event

MI: 

Myocardial infarction

MNA: 

Mini nutritional assessment

MPI: 

Multidimensional prognostic index

NYHA: 

New York Heart Association

OR: 

Odds ratio

SAVR: 

Surgical aortic valve replacement

SPMSQ: 

Short portable mental status questionnaire

SPPB: 

Short physical performance battery

STS: 

Society of thoracic surgeons

TAVI: 

Transcatheter aortic valve implantation

TIA: 

Transient ischaemic attack

TUG: 

Timed get-up and go

VARC: 

Valve Academic Research Consortium

Declarations

Acknowledgements

Data were captured using the s4trials Software provided by Software for Trials Europe GmbH, Berlin, Germany. Helen Sims and Katherine Smith (Institute for Pharmacology and Preventive Medicine; IPPMed) provided editorial support during the preparation of this manuscript.

Funding

This work was supported by a research grant that was provided by Edwards Lifesciences (Nyon, Switzerland) to the Sponsor, IPPMed (Cloppenburg, Germany). JK and MT are representatives of the funder. They discussed the study design with the principal investigators and the sponsor, had no role in data collection, had no role in the analysis, but revised the manuscript along with the other authors for important intellectual content.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author upon reasonable request.

Authors’ contributions

The authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation. The specific contributions of the respective authors are as follows: AU, PB, JK, MT, SM and AWS were involved in the conception and design of the study; GM, NvV, MT, JB, MPT, JBM, GS, MvM, and SJ collected the data, which were analyzed by AU, GM, CD, and PB and interpreted by the author group; PB drafted the manuscript and all other authors revised the article for important intellectual content. All authors have given final approval for the version to be submitted.

Ethics approval and consent to participate

All enrolled patients provided written informed consent. The study was conducted in accordance with the Declaration of Helsinki and approved by the responsible ethics committee at each participating site: Careggi Hospital, Florence, Italy (Comitato Etico Area Vasta Centro), Academic Medical Center, Amsterdam, the Netherlands (Medisch Ethische Toetsingscommissie) and Centre Hospitalier de l’Université de Montréal, Canada (Comite d’Ethique de la Recherche et du Developpement des Nouvelles Technologies).

Consent for publication

Not applicable.

Competing interests

Jan Baan and Peter Bramlage received research funding from Edwards Lifesciences, as did Andrea Ungar. Jean-Bernard Masson is a consultant for Edwards Lifesciences. Jana Kurucova is an employee of Edwards Lifesciences. The other authors declare no conflict of interest in relation to this manuscript.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Geriatric Intensive Care Unit, Department of Geriatrics and Medicine, Careggi Hospital and University of Florence, Florence, Italy
(2)
Internal Medicine, Section of Geriatric Medicine, Academic Medical Center, Amsterdam, Netherlands
(3)
Cardiology, Academic Medical Center, Amsterdam, Netherlands
(4)
Centre Hospitalier de l’Université de Montréal, Montréal, Canada
(5)
Institute for Pharmacology und Preventive Medicine, Cloppenburg, Germany
(6)
Edwards Lifesciences, Nyon, Switzerland
(7)
CNR–Institute of Neuroscience, Aging Branch, Padua, Italy
(8)
Department of Geriatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

References

  1. Bonow RO, Leon MB, Doshi D, Moat N. Management strategies and future challenges for aortic valve disease. Lancet (London, England). 2016;387(10025):1312–23.View ArticleGoogle Scholar
  2. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363(17):1597–607.View ArticlePubMedGoogle Scholar
  3. Schoenenberger AW, Stortecky S, Neumann S, Moser A, Juni P, Carrel T, Huber C, Gandon M, Bischoff S, Schoenenberger CM, et al. Predictors of functional decline in elderly patients undergoing transcatheter aortic valve implantation (TAVI). Eur Heart J. 2013;34(9):684–92.View ArticlePubMedGoogle Scholar
  4. Piazza N, Wenaweser P, van Gameren M, Pilgrim T, Tzikas A, Otten A, Nuis R, Onuma Y, Cheng JM, Kappetein AP, et al. Relationship between the logistic EuroSCORE and the society of thoracic surgeons predicted risk of mortality score in patients implanted with the CoreValve ReValving system--a Bern-Rotterdam study. Am Heart J. 2010;159(2):323–9.View ArticlePubMedGoogle Scholar
  5. Ben-Dor I, Gaglia MA Jr, Barbash IM, Maluenda G, Hauville C, Gonzalez MA, Sardi G, Laynez-Carnicero A, Torguson R, Okubagzi P, et al. Comparison between Society of Thoracic Surgeons score and logistic EuroSCORE for predicting mortality in patients referred for transcatheter aortic valve implantation. Cardiovasc Revasc Med. 2011;12(6):345–9.View ArticlePubMedGoogle Scholar
  6. Afilalo J, Mottillo S, Eisenberg MJ, Alexander KP, Noiseux N, Perrault LP, Morin JF, Langlois Y, Ohayon SM, Monette J, et al. Addition of frailty and disability to cardiac surgery risk scores identifies elderly patients at high risk of mortality or major morbidity. Circ Cardiovasc Qual Outcomes. 2012;5(2):222–8.View ArticlePubMedGoogle Scholar
  7. Afilalo J, Eisenberg MJ, Morin JF, Bergman H, Monette J, Noiseux N, Perrault LP, Alexander KP, Langlois Y, Dendukuri N, et al. Gait speed as an incremental predictor of mortality and major morbidity in elderly patients undergoing cardiac surgery. J Am Coll Cardiol. 2010;56(20):1668–76.View ArticlePubMedGoogle Scholar
  8. Otto CM, Kumbhani DJ, Alexander KP, Calhoon JH, Desai MY, Kaul S, Lee JC, Ruiz CE, Vassileva CM. 2017 ACC expert consensus decision pathway for transcatheter aortic valve replacement in the management of adults with aortic stenosis: a report of the American College of Cardiology Task Force on clinical expert consensus documents. J Am Coll Cardiol. 2017;69(10):1313–46.View ArticlePubMedGoogle Scholar
  9. Ungar A, Bramlage P, Thoenes M, Zannoni S, Michel JP. A call to action - geriatricians’ experience in treatment of aortic stenosis and involvement in transcatheter aortic valve implantation. Eur Geriatr Med. 2013;4(3):176–82.View ArticleGoogle Scholar
  10. Ellis G, Langhorne P. Comprehensive geriatric assessment for older hospital patients. Br Med Bull. 2004;71:45–59.View ArticlePubMedGoogle Scholar
  11. Lilamand M, Dumonteil N, Nourhashemi F, Hanon O, Marcheix B, Toulza O, Elmalem S, van Kan GA, Raynaud-Simon A, Vellas B, et al. Gait speed and comprehensive geriatric assessment: two keys to improve the management of older persons with aortic stenosis. Int J Cardiol. 2014;173(3):580–2.View ArticlePubMedGoogle Scholar
  12. Pilotto A, Ferrucci L, Franceschi M, D'Ambrosio LP, Scarcelli C, Cascavilla L, Paris F, Placentino G, Seripa D, Dallapiccola B, et al. Development and validation of a multidimensional prognostic index for one-year mortality from comprehensive geriatric assessment in hospitalized older patients. Rejuvenation Res. 2008;11(1):151–61.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Pilotto A, Rengo F, Marchionni N, Sancarlo D, Fontana A, Panza F, Ferrucci L. Comparing the prognostic accuracy for all-cause mortality of frailty instruments: a multicentre 1-year follow-up in hospitalized older patients. PLoS One. 2012;7(1):e29090.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Stortecky S, Schoenenberger AW, Moser A, Kalesan B, Juni P, Carrel T, Bischoff S, Schoenenberger CM, Stuck AE, Windecker S, et al. Evaluation of multidimensional geriatric assessment as a predictor of mortality and cardiovascular events after transcatheter aortic valve implantation. JACC Cardiovasc Interv. 2012;5(5):489–96.View ArticlePubMedGoogle Scholar
  15. Green P, Woglom AE, Genereux P, Daneault B, Paradis JM, Schnell S, Hawkey M, Maurer MS, Kirtane AJ, Kodali S, et al. The impact of frailty status on survival after transcatheter aortic valve replacement in older adults with severe aortic stenosis: a single-center experience. JACC Cardiovasc Interv. 2012;5(9):974–81.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Kamga M, Boland B, Cornette P, Beeckmans M, De Meester C, Chenu P, Gurne O, Renkin J, Kefer J. Impact of frailty scores on outcome of octogenarian patients undergoing transcatheter aortic valve implantation. Acta Cardiol. 2013;68(6):599–606.View ArticlePubMedGoogle Scholar
  17. Schoenenberger AW, Werner N, Bramlage P, Martinez-Selles M, Maggi S, Bauernschmitt R, Thoenes M, Kurucova J, Michel JP, Ungar A. Comprehensive geriatric assessment in patients undergoing transcatheter aortic valve implantation–rationale and design of the European CGA-TAVI registry. Eur Geriatr Med. 2014;5(1):8–13.View ArticleGoogle Scholar
  18. Katz S, Downs TD, Cash HR, Grotz RC. Progress in development of the index of ADL. The Gerontologist. 1970;10(1):20–30.View ArticlePubMedGoogle Scholar
  19. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. JAMA. 1963;185:914–9.View ArticlePubMedGoogle Scholar
  20. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. The Gerontologist. 1969;9(3):179–86.View ArticlePubMedGoogle Scholar
  21. Pfeiffer E. A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. J Am Geriatr Soc. 1975;23(10):433–41.View ArticlePubMedGoogle Scholar
  22. Conwell Y, Forbes NT, Cox C, Caine ED. Validation of a measure of physical illness burden at autopsy: the cumulative illness rating scale. J Am Geriatr Soc. 1993;41(1):38–41.View ArticlePubMedGoogle Scholar
  23. Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc. 1968;16(5):622–6.View ArticlePubMedGoogle Scholar
  24. Vellas B, Guigoz Y, Garry PJ, Nourhashemi F, Bennahum D, Lauque S, Albarede JL. The Mini Nutritional Assessment (MNA) and its use in grading the nutritional state of elderly patients. Nutrition (Burbank, Los Angeles County, Calif). 1999;15(2):116–22.View ArticleGoogle Scholar
  25. Bliss MR, McLaren R, Exton-Smith AN. Mattresses for preventing pressure sores in geriatric patients. Mon Bull Minist Health Public Health Lab Serv. 1966;25:238–68.PubMedGoogle Scholar
  26. Di Bari M, Balzi D, Roberts AT, Barchielli A, Fumagalli S, Ungar A, Bandinelli S, De Alfieri W, Gabbani L, Marchionni N. Prognostic stratification of older persons based on simple administrative data: development and validation of the “Silver Code”, to be used in emergency department triage. J Gerontol A Biol Sci Med Sci. 2010;65(2):159–64.View ArticlePubMedGoogle Scholar
  27. Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, Scherr PA, Wallace RB. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol. 1994;49(2):M85–94.View ArticlePubMedGoogle Scholar
  28. Kappetein AP, Head SJ, Genereux P, Piazza N, van Mieghem NM, Blackstone EH, Brott TG, Cohen DJ, Cutlip DE, van Es GA, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the valve academic research Consortium-2 consensus document (VARC-2). Eur J Cardiothorac Surg. 2012;42(5):S45–60.View ArticlePubMedGoogle Scholar
  29. Kodali S, Thourani VH, White J, Malaisrie SC, Lim S, Greason KL, Williams M, Guerrero M, Eisenhauer AC, Kapadia S, et al. Early clinical and echocardiographic outcomes after SAPIEN 3 transcatheter aortic valve replacement in inoperable, high-risk and intermediate-risk patients with aortic stenosis. Eur Heart J. 2016;37(28):2252–62.View ArticlePubMedGoogle Scholar
  30. Wendler O, Schymik G, Treede H, Baumgartner H, Dumonteil N, Ihlberg L, Neumann FJ, Tarantini G, Zamarano JL, Vahanian A. SOURCE 3 registry: design and 30-day results of the European Postapproval registry of the latest generation of the SAPIEN 3 transcatheter heart valve. Circulation. 2017;135(12):1123–32.View ArticlePubMedGoogle Scholar
  31. Chieffo A, Petronio AS, Mehilli J, Chandrasekhar J, Sartori S, Lefèvre T, Presbitero P, Capranzano P, Tchetche D, Iadanza A, et al. Acute and 30-day outcomes in women after TAVR: results from the WIN-TAVI (Women's INternational Transcatheter Aortic Valve Implantation) real-world registry. J Am Coll Cardiol Intv. 2016;9(15):1589–600.View ArticleGoogle Scholar
  32. Wenaweser P, Stortecky S, Heg D, Tueller D, Nietlispach F, Falk V, Pedrazzini GB, Jeger RV, Reuthebuch O, Carrel T, et al. Short-term clinical outcomes among patients undergoing transcatheter aortic valve implantation in Switzerland: the Swiss TAVI registry. EuroIntervention. 2014;10(8):982–9.View ArticlePubMedGoogle Scholar
  33. Chieffo A, Van Mieghem NM, Tchetche D, Dumonteil N, Giustino G, Van der Boon RMA, Pierri A, Marcheix B, Misuraca L, Serruys PW, et al. Impact of mixed aortic valve stenosis on VARC-2 outcomes and postprocedural aortic regurgitation in patients undergoing transcatheter aortic valve implantation. Catheter Cardiovasc Interv. 2015;86(5):875–85.View ArticlePubMedGoogle Scholar
  34. Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, Thourani VH, Tuzcu EM, Miller DC, Herrmann HC, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2016;374(17):1609–20.View ArticlePubMedGoogle Scholar
  35. Cockburn J, Dooley M, Trivedi U, De Belder A, Hildick-Smith D. A comparison between surgical risk scores for predicting outcome in patients undergoing transcatheter aortic valve implantation. J Cardiovasc Surg (Torino). 2017;58(3):467-72. doi:https://doi.org/10.23736/S0021-9509.16.09339-3. Epub 2016 Mar 16.
  36. Collas V, Chong YM, Rodrigus I, Vandewoude M, Bosmans J. Predictive mortality estimation in older patients undergoing TAVI comparison of the logistic EuroSCORE, EuroSCORE II and STS-score. Eur Geriatr Med. 2015;6(1):11–4.View ArticleGoogle Scholar
  37. Giantin V, Valentini E, Iasevoli M, Falci C, Siviero P, De Luca E, Maggi S, Martella B, Orrù G, Crepaldi G, et al. Does the Multidimensional Prognostic Index (MPI), based on a Comprehensive Geriatric Assessment (CGA), predict mortality in cancer patients? Results of a prospective observational trial. J Geriatr Oncol. 2013;4(3):208–17.View ArticlePubMedGoogle Scholar
  38. Pilotto A, Addante F, Ferrucci L, Leandro G, D'Onofrio G, Corritore M, Niro V, Scarcelli C, Dallapiccola B, Franceschi M. The multidimensional prognostic index predicts short- and long-term mortality in hospitalized geriatric patients with pneumonia. J Gerontol A Biol Sci Med Sci. 2009;64(8):880–7.View ArticlePubMedGoogle Scholar
  39. Pilotto A, Addante F, Franceschi M, Leandro G, Rengo G, D’Ambrosio P, Longo MG, Rengo F, Pellegrini F, Dallapiccola B, et al. Multidimensional prognostic index based on a comprehensive geriatric assessment predicts short-term mortality in older patients with heart failure. Circ Heart Fail. 2010;3(1):14–20.View ArticlePubMedGoogle Scholar
  40. Sancarlo D, Pilotto A, Panza F, Copetti M, Longo MG, D'Ambrosio P, D'Onofrio G, Ferrucci L, Pilotto A. A Multidimensional Prognostic Index (MPI) based on a comprehensive geriatric assessment predicts short- and long-term all-cause mortality in older hospitalized patients with transient ischemic attack. J Neurol. 2012;259(4):670–8.View ArticlePubMedGoogle Scholar
  41. Sundermann S, Dademasch A, Rastan A, Praetorius J, Rodriguez H, Walther T, Mohr FW, Falk V. One-year follow-up of patients undergoing elective cardiac surgery assessed with the comprehensive assessment of frailty test and its simplified form. Interact Cardiovasc Thorac Surg. 2011;13(2):119–23.View ArticlePubMedGoogle Scholar
  42. Arnold SV, Reynolds MR, Lei Y, Magnuson EA, Kirtane AJ, Kodali SK, Zajarias A, Thourani VH, Green P, Rodes-Cabau J, et al. Predictors of poor outcomes after transcatheter aortic valve replacement: results from the PARTNER (Placement of Aortic Transcatheter Valve) trial. Circulation. 2014;129(25):2682–90.View ArticlePubMedPubMed CentralGoogle Scholar
  43. Arnold SV, Afilalo J, Spertus JA, Tang Y, Baron SJ, Jones PG, Reardon MJ, Yakubov SJ, Adams DH, Cohen DJ. Prediction of poor outcome after transcatheter aortic valve replacement. J Am Coll Cardiol. 2016;68(17):1868–77.View ArticlePubMedPubMed CentralGoogle Scholar
  44. Afilalo J, Kim S, O'Brien S, Brennan JM, Edwards FH, Mack MJ, McClurken JB, Cleveland JC Jr, Smith PK, Shahian DM, et al. Gait speed and operative mortality in older adults following cardiac surgery. JAMA Cardiol. 2016;1(3):314–21.View ArticlePubMedGoogle Scholar
  45. Alfredsson J, Stebbins A, Brennan JM, Matsouaka R, Afilalo J, Peterson ED, Vemulapalli S, Rumsfeld JS, Shahian D, Mack MJ, et al. Gait speed predicts 30-day mortality after transcatheter aortic valve replacement: results from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. Circulation. 2016;133(14):1351–9.View ArticlePubMedGoogle Scholar
  46. Di Bari M, Salvi F, Roberts AT, Balzi D, Lorenzetti B, Morichi V, Rossi L, Lattanzio F, Marchionni N. Prognostic stratification of elderly patients in the emergency department: a comparison between the “Identification of Seniors at Risk” and the “Silver Code”. J Gerontol A Biol Sci Med Sci. 2012;67(5):544–50.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2018

Advertisement